Dasabuvir

• CAT Number: I000498
• CAS Number: 1132935-63-7
• Molecular Formula: C26H27N3O5S
• Molecular Weight: 493.5
• Purity: ≥95%
• Target: HCV
• Solubility: DMSO: ≥ 46 mg/mL
• Storage: Store at -20°C
• InChI: InChI=1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31)
• InChIKey: NBRBXGKOEOGLOI-UHFFFAOYSA-N
• SMILES: CC(C)(C)C1=C(OC)C(C2=CC3=CC=C(NS(C)(=O)=O)C=C3C=C2)=CC(N4C=CC(NC4=O)=O)=C1

Dasabuvir (CAT: I000498) is an antiviral medication used in combination therapy for the treatment of chronic hepatitis C virus (HCV) infection. It belongs to the class of drugs known as NS5B polymerase inhibitors. Dasabuvir specifically targets the HCV nonstructural protein 5B (NS5B) polymerase, which is essential for viral replication. By inhibiting NS5B polymerase, dasabuvir disrupts the replication process of HCV, ultimately reducing the viral load in the body. It is typically used in combination with other antiviral agents as part of a comprehensive treatment regimen for chronic HCV infection.

Reference

1: King JR, Zha J, Khatri A, Dutta S, Menon RM. Clinical Pharmacokinetics of
Dasabuvir. Clin Pharmacokinet. 2017 Mar 4. doi: 10.1007/s40262-017-0519-3. [Epub
ahead of print] Review. PubMed PMID: 28258380.

2: Mantry PS, Pathak L. Dasabuvir (ABT333) for the treatment of chronic HCV
genotype I: a new face of cure, an expert review. Expert Rev Anti Infect Ther.
2016;14(2):157-65. doi: 10.1586/14787210.2016.1120668. Epub 2015 Dec 17. Review.
PubMed PMID: 26567871.

3: Institute for Quality and Efficiency in Health Care. Dasabuvir and Ombitasvir
/ Paritaprevir / Ritonavir (Addendum to Commissions A15-03 and A15-04)
[Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care
(IQWiG); 2015 Jun 25. Available from http://www.ncbi.nlm.nih.gov/books/NBK385743/
PubMed PMID: 28609085.

4: Gamal N, Andreone P. Working together to tackle HCV infection:
ombitasvir/paritaprevir/ritonavir and dasabuvir combination. Drugs Today (Barc).
2015 May;51(5):303-14. doi: 10.1358/dot.2015.51.5.2332992. Review. PubMed PMID:
26097903.

5: Gentile I, Buonomo AR, Borgia G. Dasabuvir: A Non-Nucleoside Inhibitor of NS5B
for the Treatment of Hepatitis C Virus Infection. Rev Recent Clin Trials.
2014;9(2):115-23. Review. PubMed PMID: 24882169.